Recently, the Science and Technology Innovation Bureau of Yantian District, Shenzhen, issued the "Interim Measures for the Recognition and Management of Future Industry Enterprises in Yantian District, Shenzhen" (Shenyankegui [2022] No. 1). Shenzhen Hemogen Biotechnology Co., Ltd. (referred to as "Hemogen") has been successfully recognized as a future industry enterprise in the field of cellular and genetic technologies in Yantian District. This honor reflects the high recognition of the Yantian District government for Hemogen's future development potential in the field of cellular and genetic technologies

Hemogen currently has two major technology platforms, gene delivery and gene editing, and is developing multiple product pipelines in research areas such as α-thalassemia, immunodeficiency, and neurodegenerative diseases. Its independently developed HGI-001 injection successfully obtained the Clinical Trial Implicit License from the National Medical Products Administration (NMPA) of China on December 19, 2023. This recognition as a "future industry enterprise" will serve as a driving force for Hemogen's advancement, firmly establishing its determination to regard this as a new starting point for deepening technological innovation and promoting the transformation of achievements. With a commitment to professional breakthroughs, exquisite craftsmanship, climbing new heights, and sparking innovation, Hemogen continues to strive tirelessly to provide precise and effective gene therapy for patients with severe β-thalassemia, improve their quality of life, and tirelessly work towards the beautiful vision of "No Thalassemia in the World."